A detailed history of Stamos Capital Partners, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Stamos Capital Partners, L.P. holds 1,100 shares of VRTX stock, worth $552,695. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,100
Previous 1,210 9.09%
Holding current value
$552,695
Previous $505,000 1.98%
% of portfolio
0.11%
Previous 0.12%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $43,209 - $53,408
-110 Reduced 9.09%
1,100 $515,000
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $12,230 - $13,382
-30 Reduced 2.42%
1,210 $505,000
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $559,090 - $669,408
-1,630 Reduced 56.79%
1,240 $504,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $970,576 - $1.04 Million
2,870 New
2,870 $998,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Stamos Capital Partners, L.P. Portfolio

Follow Stamos Capital Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stamos Capital Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Stamos Capital Partners, L.P. with notifications on news.